Instem CSO, Dr Gordon Baxter, was recently interviewed by Drug Target Review
for an in-depth editorial on Target Safety Assessment.
Includes Powerful New In Silico Models and
First-to-Market Software Capabilities
Join the journey with us by visiting
one of our bi-weekly industry Blogs
Newly Added Services to Support Latest Regulatory Guidance and Growing Demand for Alternative Testing Methods
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support
Powerful New In Silico Models and First-to-Market Software Capabilities to Deliver Further Efficiencies and Increased Regulatory Compliance
To help you better evaluate our software or services, we believe an initial, no pressure Web session is the way to go.
© 2022 Instem Group of Companies